Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Download

Total Articles

7
(from Reference Citation Analysis)

Article PDFs (0)

Cited by > 0 (0)

Searched Name

Linzess

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Publication Title Analysis
Category Analysis

Results Analysis

Indexed Articles

Year Published

Show more Refine

Article Type

Show more Refine

Article Statistics

Refine

MESH Headings

Show more Refine

First Author

Show more Refine

First Author Affiliations

Show more Refine

Authors

Show more Refine

Publication Titles

Show more Refine

Grant Agencies

Show more Refine

Countries/Regions

Show more Refine

Affiliations

Show more Refine

Corresponding Author Affiliations

Show more Refine

Category

Show more Refine

Number	Citation Analysis
1	Linaclotide (Linzess) for functional constipation. Med Lett Drugs Ther 2023;65:135-6. [PMID: 37651297 DOI: 10.58347/tml.2023.1683d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 09/02/2023] Abstract Collapse Key Words Linzess adverse effects constipation dosage efficacy linaclotide safety Collapse MESH Headings Humans Peptides Constipation/diagnosis Constipation/drug therapy Collapse Grants Collapse Affiliation(s) Collapse
2	Vibrant - an oral vibrating capsule for chronic idiopathic constipation. Med Lett Drugs Ther 2023;65:65-67. [PMID: 37155248 DOI: 10.58347/tml.2023.1675a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/10/2023] Abstract The Vibrant orally administered vibrating capsule (Vibrant Gastro), an FDA-cleared medical device, is now available by prescription for treatment of adults with chronic idiopathic constipation (CIC) who have not experienced relief of their bowel symptoms by using laxative therapies at the recommended dosage for at least one month. It is the first drug-free treatment to be authorized by the FDA for this indication. Collapse Key Words Amitiza Dulcolax Linzess Miralax Motegrity Trulance Vibrant adverse effects bisacodyl constipation dosage efficacy linaclotide lubiprostone plecanatide polyethylene glycol prucalopride safety Collapse MESH Headings Collapse Grants Collapse Affiliation(s) Collapse
3	Tenapanor (Ibsrela) for irritable bowel syndrome with constipation. Med Lett Drugs Ther 2022;64:91-4. [PMID: 35657365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023] Abstract Collapse Key Words Amitiza Constella Ibsrela Linzess Trulance Zelnorm adverse effects dosage drug interactions efficacy irritable bowel syndrome lactation linaclotide lubiprostone plecanatide pregnancy safety tegaserod tenapanor Collapse MESH Headings Constipation/diagnosis Constipation/drug therapy Gastrointestinal Agents/adverse effects Humans Irritable Bowel Syndrome/diagnosis Irritable Bowel Syndrome/drug therapy Isoquinolines/therapeutic use Sulfonamides/therapeutic use Treatment Outcome Collapse Grants Collapse Affiliation(s) Collapse
4	Drugs for Irritable Bowel Syndrome. Med Lett Drugs Ther 2020;62:25-32. [PMID: 32324172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023] Abstract Collapse Key Words 5-HT3 antagonists 5-HT4 agonist Amitiza Anaspaz Bentyl Celexa Colestid Constipation IBgard Ibsrela Imodium Levbid Levsin Linzess Lotronex Lyrica Miralax NHE3 inhibitor Norpramin Pamelor Paxil Pepogest Prozac Questran SSRIs Trulance Viberzi Welchol Xifaxan Zelnorm Zofran adverse effects alosetron amitriptyline antibacterials antidepressants antidiarrheals antispasmodics bile acid sequestrants chloride channel activator cholestyramine citalopram colesevelam colestipol desipramine diarrhea dicyclomine diet dosage drug interactions efficacy eluxadoline exercise fiber fluoxetine guanylate cyclase-c agonists hyoscyamine irritable bowel syndrome linaclotide loperamide lubiprostone nortriptyline ondansetron opioid receptor agonist opioid receptor antagonist osmotic laxatives paroxetine peppermint oil plecanatide polyethylene glycol pregabalin probiotics psyllium rifaximin safety tegaserod tenapanor tricyclic antidepressants Collapse MESH Headings Constipation/drug therapy Constipation/etiology Diarrhea/drug therapy Diarrhea/etiology Gastrointestinal Agents/pharmacology Gastrointestinal Agents/therapeutic use Humans Irritable Bowel Syndrome/drug therapy Irritable Bowel Syndrome/physiopathology Collapse Grants Collapse Affiliation(s) Collapse
5	Table: Safety of drugs for IBS in pregnancy and lactation (online only). Med Lett Drugs Ther 2020;62:e48-9. [PMID: 32324174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [Subscribe] [Scholar Register] [Indexed: 06/11/2023] Abstract Collapse Key Words Amitiza Bentyl Celexa Colestid Ibsrela Levsin Linzess Lotronex Lyrica Motegrity Norpramin Pamelor Paxil Prozac Questran SSRIs Trulance Viberzi Welchol Xifaxan Zelnorm Zofran alosetron amitriptyline cholestyramine citalopram colesevelam colestipol desipramine dicyclomine eluxadoline fluoxetine hyoscyamine irritable bowel syndrome lactation linaclotide lubiprostone nortriptyline ondansetron paroxetine plecanatide pregabalin pregnancy prucalopride rifaximin tegaserod tenapanor tricyclic antidepressants Collapse MESH Headings Collapse Grants Collapse Affiliation(s) Collapse
6	Expanded table: some drugs for chronic idiopathic constipation. Med Lett Drugs Ther 2019;61:e88-90. [PMID: 31170121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023] Abstract Collapse Key Words Amitiza Constella Linzess Motegrity Resotran Trulance adverse effects constipation dosage efficacy linaclotide lubiprostone plecanatide pregnancy prucalopride safety Collapse MESH Headings Chronic Disease Constipation/drug therapy Constipation/physiopathology Gastrointestinal Agents/adverse effects Gastrointestinal Agents/pharmacology Gastrointestinal Agents/therapeutic use Humans Collapse Grants Collapse Affiliation(s) Collapse
7	Prucalopride (Motegrity) for chronic idiopathic constipation. Med Lett Drugs Ther 2019;61:86-8. [PMID: 31170120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023] Abstract Collapse Key Words Amitiza Constella Dulcolax Linzess Miralax Motegrity Resotran Restoralax Trulance Zelnorm adverse effects bisacodyl constipation dosage efficacy linaclotide lubiprostone plecanatide polyethylene glycol pregnancy prucalopride safety tegaserod Collapse MESH Headings Adult Benzofurans/administration & dosage Benzofurans/adverse effects Benzofurans/pharmacology Chronic Disease Constipation/drug therapy Constipation/physiopathology Humans Laxatives/administration & dosage Laxatives/adverse effects Laxatives/pharmacology Serotonin 5-HT4 Receptor Agonists/administration & dosage Serotonin 5-HT4 Receptor Agonists/adverse effects Serotonin 5-HT4 Receptor Agonists/pharmacology Collapse Grants Collapse Affiliation(s) Collapse